{"id":716,"date":"2023-06-02T22:01:21","date_gmt":"2023-06-02T22:01:21","guid":{"rendered":"https:\/\/eastmedia.lt\/markas-cubanas-yusimry-prieinamuma-mccpdc-vadina-zaidimu-keitikliu\/"},"modified":"2023-06-02T22:01:21","modified_gmt":"2023-06-02T22:01:21","slug":"markas-cubanas-yusimry-prieinamuma-mccpdc-vadina-zaidimu-keitikliu","status":"publish","type":"post","link":"https:\/\/easa.lt\/index.php\/2023\/06\/02\/markas-cubanas-yusimry-prieinamuma-mccpdc-vadina-zaidimu-keitikliu\/","title":{"rendered":"Markas Cubanas Yusimry prieinamum\u0105 MCCPDC vadina \u201e\u017eaidim\u0173 keitikliu\u201c"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.mobihealthnews.com\/sites\/default\/files\/1160710758_0.jpg\" \/><\/p>\n<div property=\"content:encoded\">\n<p dir=\"ltr\"><span id=\"docs-internal-guid-4e7861f7-7fff-fa47-b839-5894f38b7c15\">\u201eMark Cuban Cost Plus Drug Company\u201c (<\/span>MCCPDC) paskelb\u0117, kad bendradarbiauja su Coherus Biosciences, Inc., kad parduot\u0173 Yusimry, biologi\u0161kai pana\u0161i\u0105 geriausiai parduodamo vaisto Humira versij\u0105 su nuolaida. <\/p>\n<p dir=\"ltr\"><span id=\"docs-internal-guid-4e7861f7-7fff-fa47-b839-5894f38b7c15\">Yusimry vartojamas kelioms ligoms, tokioms kaip reumatoidinis artritas, psoriazinis artritas, jaunatvinis idiopatinis artritas, ankilozuojantis spondilitas, opinis kolitas, p\u016blingas hidradenitas, Krono liga ir plok\u0161telin\u0117 psoriaz\u0117, gydyti.<\/span><\/p>\n<p dir=\"ltr\"><span id=\"docs-internal-guid-4e7861f7-7fff-fa47-b839-5894f38b7c15\">Vaistus bus galima \u012fsigyti per MCCPDC nuo 2023 m. liepos m\u0117n., jis kainuos 569,27 USD, prid\u0117jus i\u0161davimo ir pristatymo mokes\u010dius.  Tai bus pirmasis biologinis produktas, kur\u012f si\u016blo pigi\u0173 vaist\u0173 tiek\u0117jas. <\/span><\/p>\n<p dir=\"ltr\"><span id=\"docs-internal-guid-4e7861f7-7fff-fa47-b839-5894f38b7c15\">Vasario m\u0117n. MCCPDC paskelb\u0117 apie nauj\u0105 program\u0105 <\/span><a href=\"https:\/\/twitter.com\/costplusdrugs\/status\/1624576978836721664\" target=\"_blank\" rel=\"noopener\">Twitter<\/a>, kuria siekiama sukurti nepriklausom\u0105 vaistinink\u0173 tinkl\u0105, kurio nariams b\u016bt\u0173 suteikta \u201eKomandos Kubos i\u0161mok\u0173 kortel\u0117\u201c.  MCCPDC prane\u0161ime teigiama, kad Yusimry bus \u012ftrauktas \u012f i\u0161mok\u0173 program\u0105 per dalyvaujan\u010dias vaistines. <\/p>\n<p dir=\"ltr\"><span id=\"docs-internal-guid-4e7861f7-7fff-fa47-b839-5894f38b7c15\">&#8222;Coherus&#8217;s Yusimry yra \u017eaidimo pakeitimo priemon\u0117. \u012eperkama Humira alternatyva pagerins pacient\u0173 gyvenim\u0105 visur. Costplusdrugs.com tikrai d\u017eiaugiasi gal\u0117dama padaryti Yusimry prieinam\u0105 visiems skaidriai&#8221;, \u2013 sak\u0117 Markas Cubanas. <\/span><em>\u201eMobiHealthNews\u201c.<\/em> el. lai\u0161ke. <\/p>\n<p dir=\"ltr\"><strong><span id=\"docs-internal-guid-4e7861f7-7fff-fa47-b839-5894f38b7c15\">DIDESN\u0116 TENDENCIJA<\/span><\/strong><\/p>\n<p dir=\"ltr\"><span id=\"docs-internal-guid-4e7861f7-7fff-fa47-b839-5894f38b7c15\">Nuo <\/span>MCCPDC<span>Prad\u0117jusi veikti 2022 m., ji u\u017emezg\u0117 daugyb\u0119 partnerys\u010di\u0173 ir bendradarbiavimo.<\/span><\/p>\n<p dir=\"ltr\"><span id=\"docs-internal-guid-4e7861f7-7fff-fa47-b839-5894f38b7c15\">Baland\u012f bendrov\u0117 paskelb\u0117 apie bendradarbiavim\u0105 su Sietle <\/span>\u201eZ\u00f3calo Health\u201c \u2013 virtuali sveikatos prie\u017ei\u016bros paslauga, skirta Lotyn\u0173 Amerikos pacientams, siekiant i\u0161pl\u0117sti \u201eZ\u00f3calo\u201c nari\u0173 prieig\u0105 prie pigesni\u0173 receptini\u0173 vaist\u0173. <\/p>\n<p dir=\"ltr\"><span id=\"docs-internal-guid-4e7861f7-7fff-fa47-b839-5894f38b7c15\">T\u0105 pat\u012f m\u0117nes\u012f, <\/span>\u201eFierce Healthcare\u201c prane\u0161\u0117, kad MCCPDC kartu su sveikatos mok\u0117jimo sprendim\u0173 bendrove \u201eRevSpring\u201c vykdo program\u0105 su JAV vaistin\u0117mis, kad vaistai b\u016bt\u0173 prieinamesni vartotojams. <\/p>\n<p dir=\"ltr\"><span id=\"docs-internal-guid-4e7861f7-7fff-fa47-b839-5894f38b7c15\">MCCPDC taip pat u\u017emezg\u0117 partneryst\u0119 su Kalifornijoje \u012fsik\u016brusia bendrove <\/span>\u201eEmsanaRx\u201c ir Tenesyje \u012fsik\u016brusi \u201eRxPreferred Benefits\u201c ir paskelb\u0117 apie bendradarbiavim\u0105 su diabeto ir l\u0117tini\u0173 lig\u0173 valdymo \u012fmone \u201eDiathrive Health\u201c ir v\u0117\u017eio prie\u017ei\u016bros palaikymo \u012fmone \u201eOncoPower\u201c.<\/p>\n<p dir=\"ltr\"><span id=\"docs-internal-guid-4e7861f7-7fff-fa47-b839-5894f38b7c15\">MCCPDC taip pat buvo integruotas \u012f <\/span>\u201eRightway Health\u201c platforma, leid\u017eianti vaistin\u0117s i\u0161mok\u0173 valdytojo nariams pasiekti MCCPDC. <\/p>\n<p dir=\"ltr\"><span id=\"docs-internal-guid-4e7861f7-7fff-fa47-b839-5894f38b7c15\">Pra\u0117jusiais metais bendrov\u0117 taip pat paskelb\u0117 apie savo pirm\u0105j\u0105 sveikatos plano partneryst\u0119 su <\/span>\u201eCapital Blue Cross\u201c pa\u017eymi, kad nuo 2023 m. \u201eCapital\u201c nariai savo draudimo kortel\u0117mis gali naudotis tiesiogiai MCCPDC.<\/p>\n<\/div>\n<p><script async src=\"\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u201eMark Cuban Cost Plus Drug Company\u201c (MCCPDC) paskelb\u0117, kad bendradarbiauja su Coherus Biosciences, Inc., kad parduot\u0173 Yusimry, biologi\u0161kai pana\u0161i\u0105 geriausiai parduodamo vaisto Humira versij\u0105 su nuolaida. Yusimry vartojamas kelioms ligoms, tokioms kaip reumatoidinis artritas, psoriazinis artritas, jaunatvinis idiopatinis artritas, ankilozuojantis spondilitas, opinis kolitas, p\u016blingas hidradenitas, Krono liga ir plok\u0161telin\u0117 psoriaz\u0117, gydyti. Vaistus bus galima \u012fsigyti [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":715,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-716","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bendri"],"_links":{"self":[{"href":"https:\/\/easa.lt\/index.php\/wp-json\/wp\/v2\/posts\/716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/easa.lt\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/easa.lt\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/easa.lt\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/easa.lt\/index.php\/wp-json\/wp\/v2\/comments?post=716"}],"version-history":[{"count":0,"href":"https:\/\/easa.lt\/index.php\/wp-json\/wp\/v2\/posts\/716\/revisions"}],"wp:attachment":[{"href":"https:\/\/easa.lt\/index.php\/wp-json\/wp\/v2\/media?parent=716"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/easa.lt\/index.php\/wp-json\/wp\/v2\/categories?post=716"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/easa.lt\/index.php\/wp-json\/wp\/v2\/tags?post=716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}